Feng Chi BiotechROCO:6744 -1.32%82 ROE % is 4.76% as of Dec. 2025, which is 52% below its 10-year median of 9.89. GuruFocus rates ROCO:6744 with a GF Score™ of 82/100 and a GF Value™ of NT$20.86 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,251 Biotechnology companies, Feng Chi Biotech ranks better than 84.73% on this metric.
The historical rank and industry rank for Feng Chi Biotech's ROE % or its related term are showing as below:
ROCO:6744'
s ROE % Range Over the Past 10 Years
Min: 6.03 Med: 9.89 Max: 11.89
Current: 6.09
During the past 10 years, Feng Chi Biotech's highest ROE % was 11.89%. The lowest was 6.03%. And the median was 9.89%.
ROCO:6744's ROE % is ranked better than 84.73% of 1251
companies
in the Biotechnology industry
Industry Median: -38.11
vs ROCO:6744: 6.09
Feng Chi Biotech (ROCO:6744) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Feng Chi Biotech ROE % Related Terms
Feng Chi Biotech ROE % Historical Data
* Premium members only.
The historical data trend for Feng Chi Biotech's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Feng Chi Biotech's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Feng Chi Biotech ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Feng Chi Biotech's ROE % distribution charts can be found below:
* The bar in red indicates where Feng Chi Biotech's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Feng Chi Biotech (ROCO:6744) has a ROE % of 4.76% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Feng Chi Biotech and its competitors. This is 52% below median its historical median of 9.89. Over the past decade, Feng Chi Biotech's ROE % has ranged from 6.03 to 11.89. According to the industry distribution chart, Feng Chi Biotech ranks #191 out of 1251 companies in the Biotechnology industry, placing it in the top 15.3%.
Is Feng Chi Biotech's ROE % too high?
Feng Chi Biotech's current ROE % of 4.76% is 52% below median its 10-year median of 9.89. Over the past 10 years, this metric has ranged from a low of 6.03 to a high of 11.89. Based on the distribution chart, Feng Chi Biotech ranks #191 out of 1251 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Feng Chi Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Feng Chi Biotech's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Feng Chi Biotech ranks #191 out of 1251 companies for ROE %. This places Feng Chi Biotech in the top 15% of its industry — outperforming the majority of peers. Historically, Feng Chi Biotech's own ROE % has ranged from 6.03 to 11.89 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Feng Chi Biotech and its competitors. Feng Chi Biotech's current ROE % is 4.76%, which is 52% below median its own 10-year median of 9.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Feng Chi Biotech stock overvalued right now?
Based on GuruFocus' analysis, Feng Chi Biotech (ROCO:6744) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$20.86, compared to a current price of NT$15.00 — trading 28.1% below its estimated fair value. The current ROE % is 4.76%, which is 52% below median its 10-year median of 9.89. Feng Chi Biotech's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Feng Chi Biotech (ROCO:6744), the current ROE % is 4.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Feng Chi Biotech (ROCO:6744) Overvalued in 2026?
Based on GuruFocus' analysis, Feng Chi Biotech stock appears to be undervalued.
The current stock price of NT$15.00 is trading 28.1% below its estimated GF Value™ of NT$20.86.
GuruFocus considers Feng Chi Biotech to be Modestly Undervalued.
Key valuation signals for ROCO:6744:
ROE %: 4.76% (52% below median its 10-year median of 9.89)
GF Value™: NT$20.86 vs. price of NT$15.00 (28.1% below fair value)
No single metric tells the full story. See the ROCO:6744 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Feng Chi Biotech Corp provide promotion and support for clinical testing and molecular genetic medicine research related technologies. The company's products and services include clinical testing, food testing, newborn screening, prenatal screening, iron stomach, interscience, and colony counting.
82GF Score
Get the complete analysis for ROCO:6744
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6744 has been successfully added to your 
